© 2020 RSM US LLP. All rights reserved.
Tax Services for the Life Sciences Industry
Identifying opportunities to minimize tax and compliance burdens
Life sciences companies face a variety of tax considerations from the affects of tax reform to the benefits of R&D credits, to intellectual property planning and global reporting and compliance. Proper tax planning is imperative in order to avoid unnecessary tax exposure and minimize risk.
RSM’s tax professionals provide specific life sciences tax consulting to companies on a variety of tax matters that include credits and incentives, state and local issues, and international tax planning.
Three states have prescriptions for opioid taxes on manufacturers and distributors. Here’s what you need to know.
Notwithstanding unfavorable changes to the Code, capital gain treatment is still available on the sale of patents in certain scenarios.
Active trade or business present in subsidiary without independent current revenue but with a plan to make future product sales.
New life sciences businesses can earn up to a maximum tax benefit of $1.5 million in tax credits over three years.
The IRS is reconsidering the traditional rule requiring revenue to satisfy the active trade or business requirement of section 355.
Missed our recent webcast on how the Tax Cuts and Jobs Act will affect life sciences companies? Check out our recap.
A review of IRS rulings on the proper treatment of similar expenses that were incurred by a pharmaceutical company.
Covance, a life sciences company, wanted to improve its approach to managing global reporting and compliance requirements.
Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.
This recorded webcast gives an overview of how, when and why biopharma companies should invest in enterprise resource planning systems.
This webcast gives an overview of the top considerations for life sciences companies looking to repatriate or nearshore supply chains.
With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.
We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.
For companies that may have dealt with a lab closure because of the pandemic, Scientist.com allows research to continue.
Amid the COVID-19 pandemic, life sciences companies, thrust in the spotlight, are positioned for strong growth.
Whether developing drug therapies, designing medical devices, or more, life sciences companies have complex technology needs.
The IRS updated taxpayers on its operations status and recognized the delays in processing check payments due on July 15, 2020.
Applications to sell unused state net operating losses and state research and development credits available the week of May 1, 2020.